GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (STU:S2P) » Definitions » Research & Development

Simcere Pharmaceutical Group (STU:S2P) Research & Development : €183.2 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Simcere Pharmaceutical Group Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Simcere Pharmaceutical Group's Research & Development for the six months ended in Dec. 2024 was €110.7 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 was €183.2 Mil.

Simcere Pharmaceutical Group Research & Development Historical Data

The historical data trend for Simcere Pharmaceutical Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Research & Development Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial 143.55 196.85 234.02 200.75 184.96

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 145.80 100.00 101.10 72.50 110.71

Simcere Pharmaceutical Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €183.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simcere Pharmaceutical Group  (STU:S2P) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Simcere Pharmaceutical Group Research & Development Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (STU:S2P) » Definitions » Research & Development
Comparable Companies
HKSE:00512 HKSE:00867 HKSE:03933 HKSE:03320 HKSE:06185 HKSE:01558 HKSE:00570 HKSE:02005 HKSE:01681 HKSE:02186 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
02096:Hong Kong
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Website
https://www.simcere.com
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Simcere Pharmaceutical Group Headlines

No Headlines